Codiak BioSciences, Inc.
Codiak BioSciences, Inc. (CDAK): 3 pipeline candidates · ~17 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
17.1 months
D/E 2.45 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Codiak BioSciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$55.9M
Quarterly Burn
$10.1M
Runway
17.1 mo
Revenue
$522K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| exoaso-stat6 | Preclinical |
| exoil-12 | Phase 1 |
| exosting | Phase 2 |
Frequently asked questions
How many drug candidates are in Codiak BioSciences, Inc.'s pipeline?
Codiak BioSciences, Inc. (CDAK) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Codiak BioSciences, Inc.'s lead drug candidate?
Codiak BioSciences, Inc.'s most advanced tracked candidate is exoaso-stat6 (Preclinical) for primary cancers of the liver.
What is Codiak BioSciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Codiak BioSciences, Inc. has approximately 17.1 months of cash runway.
Who is the CEO of Codiak BioSciences, Inc.?
Douglas E. Williams, Ph.D. is the chief executive officer of Codiak BioSciences, Inc. (CDAK).
Get the full picture on Codiak BioSciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.